New York State Common Retirement Fund Sells 2,600 Shares of Moderna, Inc. (NASDAQ:MRNA)

New York State Common Retirement Fund lowered its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 0.6% in the fourth quarter, HoldingsChannel reports. The fund owned 398,132 shares of the company’s stock after selling 2,600 shares during the period. New York State Common Retirement Fund’s holdings in Moderna were worth $16,554,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in MRNA. Blue Trust Inc. increased its holdings in Moderna by 365.6% in the third quarter. Blue Trust Inc. now owns 731 shares of the company’s stock valued at $49,000 after purchasing an additional 574 shares during the last quarter. Raymond James & Associates increased its holdings in Moderna by 19.7% in the third quarter. Raymond James & Associates now owns 162,074 shares of the company’s stock valued at $10,831,000 after purchasing an additional 26,657 shares during the last quarter. International Assets Investment Management LLC increased its holdings in Moderna by 10,687.1% in the third quarter. International Assets Investment Management LLC now owns 319,514 shares of the company’s stock valued at $21,353,000 after purchasing an additional 316,552 shares during the last quarter. Assenagon Asset Management S.A. increased its holdings in Moderna by 79.0% in the third quarter. Assenagon Asset Management S.A. now owns 13,159 shares of the company’s stock valued at $879,000 after purchasing an additional 5,807 shares during the last quarter. Finally, E. Ohman J or Asset Management AB bought a new stake in Moderna in the third quarter valued at about $942,000. Institutional investors own 75.33% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on MRNA. Hsbc Global Res upgraded Moderna from a “hold” rating to a “strong-buy” rating in a report on Monday, November 18th. Piper Sandler restated an “overweight” rating and issued a $69.00 price target (down from $115.00) on shares of Moderna in a report on Monday, November 18th. JPMorgan Chase & Co. set a $45.00 price target on Moderna in a report on Friday, February 14th. Morgan Stanley lowered their price target on Moderna from $70.00 to $38.00 and set an “equal weight” rating for the company in a report on Wednesday, January 15th. Finally, Wolfe Research assumed coverage on Moderna in a report on Friday, November 15th. They issued an “underperform” rating and a $40.00 price target for the company. Four investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Moderna has an average rating of “Hold” and a consensus target price of $60.63.

Insider Activity at Moderna

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the firm’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the sale, the insider now owns 19,717 shares of the company’s stock, valued at $843,690.43. This trade represents a 6.71 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders have sold a total of 2,664 shares of company stock valued at $115,210 in the last 90 days. 15.70% of the stock is owned by corporate insiders.

Moderna Stock Up 5.3 %

NASDAQ MRNA opened at $35.53 on Friday. Moderna, Inc. has a twelve month low of $29.25 and a twelve month high of $170.47. The company has a market cap of $13.67 billion, a price-to-earnings ratio of -3.83 and a beta of 1.59. The business’s fifty day moving average is $38.04 and its 200 day moving average is $52.66.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.